IL6 and COVID-19: In addition to being related to viral infection, studies have shown that the overproduction of IL-6 is associated with lung damage, which can explain why IL-6 receptor blockers are among the most-suggested treatments for COVID-19 (Stone et al., 2020; Gordon et al., 2021; Salama et al., 2021).